Genmab A/S Files 6-K for Registration Statement Updates
Ticker: GNMSF · Form: 6-K · Filed: Jun 24, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, registration-statement, administrative
Related Tickers: GMAB
TL;DR
Genmab 6-K filed, nothing new financially, just housekeeping for stock registration.
AI Summary
Genmab A/S filed a Form 6-K on June 24, 2024, to be incorporated by reference into its existing S-8 registration statements. This filing does not contain new financial information but serves to update or supplement previously filed documents.
Why It Matters
This filing indicates Genmab A/S is maintaining its registration statements, which are often used for employee stock plans or other equity issuances, suggesting ongoing corporate actions related to its equity.
Risk Assessment
Risk Level: low — The filing is a routine administrative update and does not disclose new material financial or operational information that would typically impact risk.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-009432 (filing_id) — Accession Number
- 20240624 (date) — Filing Date
- 333-232693 (registration_statement_id) — Incorporated by reference in S-8 registration statement
- 333-253519 (registration_statement_id) — Incorporated by reference in S-8 registration statement
- 333-262970 (registration_statement_id) — Incorporated by reference in S-8 registration statement
- 333-277273 (registration_statement_id) — Incorporated by reference in S-8 registration statement
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The purpose of this Form 6-K filing is to be incorporated by reference into Genmab A/S's existing registration statements on Form S-8 (File Nos. 333-232693, 333-253519, 333-262970 and 333-277273).
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on June 24, 2024.
Does this filing contain new financial information for Genmab A/S?
No, this filing is a report of a foreign private issuer and is primarily for incorporation by reference into existing registration statements, not for disclosing new financial information.
What type of registration statements are being referenced?
The filing references registration statements on Form S-8.
What is the principal executive office address of Genmab A/S?
The principal executive office address is Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 236 words · 1 min read · ~1 pages · Grade level 13.8 · Accepted 2024-06-24 15:13:38
Filing Documents
- tmb-20240624x6k.htm (6-K) — 22KB
- tmb-20240624xex99d1.htm (EX-99.1) — 66KB
- tmb-20240624xex99d1a.htm (EX-99.1(A)) — 34400KB
- tmb-20240624xex99d1001.jpg (GRAPHIC) — 5KB
- tmb-20240624xex99d1a_a001.jpg (GRAPHIC) — 5KB
- tmb-20240624xex99d1a_b001.jpg (GRAPHIC) — 5KB
- 0001558370-24-009432.txt ( ) — 34508KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: JUNE 24, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated June 24, 2024: Transactions in Connection with Share Buy-back Program 99.1(a) Appendix Share buyback program – Specification for June 17 – June 21, 2024